From groundbreaking vaccines to leading academic research, the UK has made substantial, transformative contributions to human health. However, I’ve seen firsthand that maintaining UK leadership in the competitive world of clinical trials has been challenging in recent years.
According to the Association of the British Pharmaceutical Industry (ABPI), the number of UK pharmaceutical industry clinical trials plummeted by 41% between 2017 and 2021. The 2023 O’Shaughnessy Review shone a light on the inadequacies in UK clinical trials and provided recommendations for change.
Check out the rest of the feature here
